Privigen Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The privigen market research report is one of a series of new reports that provides privigen market statistics, including privigen industry global market size, regional shares, competitors with a privigen market share, detailed privigen market segments, market trends and opportunities, and any further data you may need to thrive in the privigen industry. This privigen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to improving formulations, globalization of the pharmaceutical supply chain, growth in outpatient care facilities, growth in medical tourism, and support for patient advocacy groups. Major trends in the forecast period include advancements in diagnostic capabilities, innovation in immunoglobulin therapy, advancements in drug delivery systems, advances in biotechnology, and innovations in infusion techniques.

The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the Privigen market in the coming years. Immunodeficiency disorders impair the immune system’s ability to protect the body against infections and diseases. This rise is attributed to factors such as greater awareness, improved diagnostic tools, longer survival rates for individuals with primary immunodeficiencies, increased use of immunosuppressive therapies, and higher rates of chronic conditions. Privigen, an intravenous immunoglobulin (IVIG), helps treat these disorders by boosting antibody levels, aiding patients in fighting infections and maintaining effective immune system function. For example, in May 2023, the University of Oxford reported that 19 common autoimmune diseases affected 3-9% of the UK population in 2022, with that number increasing to 10% in 2023. As a result, the growing prevalence of immunodeficiency disorders is contributing to the market expansion of Privigen.

The growth of the Privigen market is also supported by favorable government initiatives. These initiatives are programs, policies, or actions implemented by governments to improve public health, expand access to healthcare services, and enhance the well-being of populations. Government actions are increasing due to factors such as rising demand for affordable healthcare, addressing aging populations, chronic diseases, and advancements in medical technology. Initiatives supporting the treatment of immunodeficiencies are enhancing access to therapies such as Privigen by ensuring timely and affordable care through funding and healthcare programs. For instance, in February 2023, the UK’s National Institute for Health and Care Research reported that funding for the NIHR BioResource, which focuses on research to develop new tests and treatments for rare diseases, including immunodeficiencies, reached $1.0 billion in 2023, up from $50.89 million in 2022. Such government initiatives are driving the demand for Privigen.

Increased healthcare expenditure is another factor expected to propel the growth of the privigen market. Healthcare expenditure encompasses the financial resources spent on medical services, infrastructure, pharmaceuticals, and related activities. This expenditure is rising due to factors such as higher operational costs in healthcare facilities, the growing prevalence of chronic and lifestyle-related diseases, a rise in genetic disorders, advances in medical technology, and broader access to healthcare services. As healthcare spending increases, access to therapies such as Privigen improves, enhancing treatment availability, patient outcomes, and overall healthcare infrastructure. For example, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in 2022. In addition, long-term health and social care expenditure rose by 2.8% in real terms in 2022. As healthcare expenditure grows, it boosts the availability and accessibility of treatments such as Privigen.

The key company operating in the privigen market is CSL Behring AG

North America was the largest region in the privigen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in privigen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the privigen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Privigen is an intravenous immunoglobulin (IVIg) therapy derived from human plasma, primarily used to manage conditions associated with weakened immune systems. It is indicated for diseases such as primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP). Privigen boosts immunity by providing antibodies that help the body fight infections and regulate immune responses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of privigen include a liquid (10% solution) and lyophilized form. The liquid form is a sterile IVIg preparation used to treat immunodeficiency and autoimmune disorders by supplying essential antibodies. It is used for conditions such as primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, and others. Privigen is administered in various settings, including hospitals, clinics, and home care environments.

The privigen market consists of sales of privigen liquid for primary immunodeficiency, liquid for chronic immune thrombocytopenic purpura, and liquid for chronic inflammatory demyelinating polyneuropathy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.